Extracorporeal Shockwave Therapy For Diabetic Foot Wounds - Version 1
Research type
Research Study
Full title
Extracorporeal Shockwave Therapy (ECSWT)for Diabetic Foot Wounds A cohort study comparing extracorporeal shockwave therapy to standard wound treatment for diabetic foot wounds
IRAS ID
233543
Contact name
George Smith
Contact email
Sponsor organisation
Hull and East Yorkshire Hospitals
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Diabetes affects around 3.5 million people in the UK. A tenth of the patients will develop a diabetic foot wound, which over one third will not heal. Diabetes is the leading cause of non-traumatic amputation. Diabetic foot wounds have a poor healing rate post operatively, predisposing patients to further complications and chronic wounds.
Current treatment of diabetic foot wounds involves regular dressing changes, offloading the foot, debridement and larvae therapy. Complex therapies include bioengineered skin equivalents. New potential therapies include hyperbaric oxygen therapy, bone marrow derived stem cells and extracorporeal shockwave therapy.
Extracorporeal shockwave has shown improved wound healing in chronic diabetic lower limb ulcers, chronic venous ulcers and burns. Extracorporeal shockwave therapy is a non-invasive, safe and effective treatment for improving wound healing. Currently there is equivocal evidence of the benefits of shockwave therapy and therefore evidence base in diabetic wound care.
The study aims to investigate effect on wound volume of extracorporeal shockwave therapy in diabetic foot wounds post operatively and investigate tolerability of the treatment. The study will also record amputation rate, infection rate, tissue perfusion and effect on patient's pain and quality of life.
REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
17/YH/0334
Date of REC Opinion
30 Oct 2017
REC opinion
Further Information Favourable Opinion